Literature DB >> 10701389

Pharmaceutical policies in Canada: another example of federal-provincial discord.

A H Anis1.   

Abstract

Pharmaceutical policy in Canada is set at both the federal and provincial levels of government. The federal government is responsible for intellectual property rights of manufacturers (patents) and the initial approval and labelling of prescription drugs and for ensuring overall market competitiveness. The provincial government has responsibility and jurisdiction over the funding of all health care services, including pharmaceuticals. Various interactions between the pharmaceutical industry, the federal and provincial governments and consumers have shaped the current landscape for prescription drugs in Canada. One key failing of the system is that the federal government is almost completely insulated from the impact of its policies because, although it regulates drug prices, it does not buy any drugs. In contrast, provincial governments have no jurisdiction over market competitiveness or pricing, yet end up paying for most of the drug expenditures incurred.

Mesh:

Year:  2000        PMID: 10701389      PMCID: PMC1231173     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  7 in total

1.  Evaluating reference-based pricing: initial findings and prospects.

Authors:  L Narine; M Senathirajah; T Smith
Journal:  CMAJ       Date:  1999-08-10       Impact factor: 8.262

2.  Price regulation of pharmaceuticals in Canada.

Authors:  A H Anis; Q Wen
Journal:  J Health Econ       Date:  1998-01       Impact factor: 3.883

3.  Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions.

Authors:  R J Lipsy
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

4.  Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada.

Authors:  A S Detsky
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

5.  Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics.

Authors:  G W Torrance; D Blaker; A Detsky; W Kennedy; F Schubert; D Menon; P Tugwell; R Konchak; E Hubbard; T Firestone
Journal:  Pharmacoeconomics       Date:  1996-06       Impact factor: 4.981

6.  Substitution laws, insurance coverage, and generic drug use.

Authors:  A H Anis
Journal:  Med Care       Date:  1994-03       Impact factor: 2.983

7.  Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.

Authors:  C Bourgault; E Elstein; J Le Lorier; S Suissa
Journal:  CMAJ       Date:  1999-08-10       Impact factor: 8.262

  7 in total
  12 in total

Review 1.  Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.

Authors:  Lisa L Ioannides-Demos; Joseph E Ibrahim; John J McNeil
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  The effect of pharmaceutical patent term length on research and development and drug expenditures in Canada.

Authors:  Paul Grootendorst; Livio Di Matteo
Journal:  Healthc Policy       Date:  2007-02

3.  How to pay for national pharmacare.

Authors:  Michael C Wolfson; Steven G Morgan
Journal:  CMAJ       Date:  2018-11-26       Impact factor: 8.262

4.  Children in need of Pharmacare: medication funding requests at the Toronto Hospital for Sick Children.

Authors:  Wendy J Ungar; Carolyn Daniels; Ted McNeill; Mahdie Seyed
Journal:  Can J Public Health       Date:  2003 Mar-Apr

5.  Amiodarone-induced thyroid dysfunction: brand-name versus generic formulations.

Authors:  Meytal A Tsadok; Cynthia A Jackevicius; Elham Rahme; Vidal Essebag; Mark J Eisenberg; Karin H Humphries; Jack V Tu; Hassan Behlouli; Jennifer Joo; Louise Pilote
Journal:  CMAJ       Date:  2011-07-11       Impact factor: 8.262

6.  Influencing Drug Prices through Formulary-Based Policies: Lessons from New Zealand.

Authors:  Steve Morgan; Gillian Hanley; Meghan McMahon; Morris Barer
Journal:  Healthc Policy       Date:  2007-08

7.  Public drug plan coverage for children across Canada: a portrait of too many colours.

Authors:  Wendy J Ungar; Maciej Witkos
Journal:  Healthc Policy       Date:  2005-09

8.  A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada.

Authors:  Steven G Morgan; Marc-André Gagnon; Barbara Mintzes; Joel Lexchin
Journal:  Healthc Policy       Date:  2016-08

9.  Pharmacists remuneration models in iran and selected countries: a comparative study.

Authors:  Amir Hashemi-Meshkini; Khosro Keshavarz; Shekoufeh Nikfar; Iman Vazirian; Abbas Kebriaeezadeh
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

10.  The content of patient counseling about interchangeable medicines and generic substitution in Finnish community pharmacies - a survey of dispensers.

Authors:  Riikka Rainio; Riitta Ahonen; Johanna Timonen
Journal:  BMC Health Serv Res       Date:  2019-12-11       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.